Search research articles
Contact Us
Filters
Showing results (61-70 of 114) with videos related to
Page
of 12
Sort By:
Hematological Oncology
|
June 14, 2024
Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy
Danai Dima, Utkarsh Goel, Aishwarya Sannareddy, et al.
Blood
|
September 27, 2024
Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study
Ashraf Badros, Laahn Foster, Larry D Anderson, et al.
British Journal of Haematology
|
February 14, 2018
Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results
Paul G Richardson, William I Bensinger, Carol Ann Huff, et al.
Blood
|
June 3, 2026
Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myeloma
Susan Bal, Myo Htut, Omar Nadeem, et al.
British Journal of Haematology
|
September 16, 2022
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study
Douglas W Sborov, Muhamed Baljevic, Brandi Reeves, et al.
Blood Advances
|
January 9, 2025
Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study
Othman Salim Akhtar, Temitope Oloyede, Ruta Brazauskas, et al.
Transplantation and Cellular Therapy
|
November 15, 2021
Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation
Surbhi Sidana, Shaji Kumar, Raphael Fraser, et al.
European Journal of Haematology
|
September 8, 2021
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
Paul G Richardson, Fredrik Schjesvold, Katja Weisel, et al.
Haematologica
|
October 19, 2023
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience
Hamza Hashmi, Doris K Hansen, Lauren C Peres, et al.
The New England Journal of Medicine
|
February 24, 2021
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C Munshi, Larry D Anderson, Nina Shah, et al.
Page
of 12
Search research articles
Search
Showing results (61-70 of 114) with videos related to
Sort By:
Page
of 12
Hematological Oncology
|
June 14, 2024
Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy
Danai Dima, Utkarsh Goel, Aishwarya Sannareddy, et al.
Blood
|
September 27, 2024
Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study
Ashraf Badros, Laahn Foster, Larry D Anderson, et al.
British Journal of Haematology
|
February 14, 2018
Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results
Paul G Richardson, William I Bensinger, Carol Ann Huff, et al.
Blood
|
June 3, 2026
Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myeloma
Susan Bal, Myo Htut, Omar Nadeem, et al.
British Journal of Haematology
|
September 16, 2022
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study
Douglas W Sborov, Muhamed Baljevic, Brandi Reeves, et al.
Blood Advances
|
January 9, 2025
Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study
Othman Salim Akhtar, Temitope Oloyede, Ruta Brazauskas, et al.
Transplantation and Cellular Therapy
|
November 15, 2021
Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation
Surbhi Sidana, Shaji Kumar, Raphael Fraser, et al.
European Journal of Haematology
|
September 8, 2021
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
Paul G Richardson, Fredrik Schjesvold, Katja Weisel, et al.
Haematologica
|
October 19, 2023
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience
Hamza Hashmi, Doris K Hansen, Lauren C Peres, et al.
The New England Journal of Medicine
|
February 24, 2021
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C Munshi, Larry D Anderson, Nina Shah, et al.
Page
of 12